9q deletions of fatigue, muscle cramps, short stature, delayed puberty, sensorineural hearing loss (SNHL), and mild developmental delay. The SNHL was bilateral, moderate to severe with 35-113 dB loss across all frequencies. CMA techniques have been used in these patients to identify precise chromosomal breakpoints. These breakpoints were compared to other published cases analyzed with CMA.
| CLINICAL REPORT

| Index case
The proband, IV1 in Figure 1 , is the second child of nonconsanguineous parents and had an uncomplicated antenatal period being delivered at term. The patient presented for clinical genetic assessment at 11 years of age and is currently 19 years of age. He presented, at 11 years of age, with symptoms of muscle pain and cramps, beginning in the toes and progressing to the feet and calves. He experienced significant fatigue on most days with significant muscle weakness after light activity. He also has post-lingual bilateral, moderate to severe SNHL of 35-60 dB loss across all frequencies.
Neurological examination was unremarkable with normal gait, no proximal weakness, normal peripheral tone, power, reflexes, and sensation. Cranial nerve examination was also normal with no ptosis observed on sustained upward gaze. There was no clear evidence of fatigability consistent with a myasthenia syndrome, and subsequent nerve conduction studies were also normal. He was not dysmorphic, had a normal cardiac examination, and no clinical features to suggest a skeletal dysplasia. At 11 years of age, his weight at this stage was 29 kg (3rd percentile) and height 139.4 cm (1st percentile). His annual growth velocity at the time was 4.2 cm/y (<25th percentile). There were no signs of puberty. X-rays were undertaken demonstrating a bone age of 11 years (10th percentile). A formal skeletal survey was normal with no radiological signs of a skeletal dysplasia. A growth hormone (GH) stimulation test was normal. Hormone testing revealed normal FSH and LH levels (both 1.8 mIU/mL) and a low testosterone level (1.2 mIU/mL). A testicular ultrasound measured his testes at 2.6 and 3.3 cm. He commenced pubertal induction with testosterone injections, which induced a 15 cm growth spurt to a height of 168 cm at 19 years of age.
Normal results were obtained for creatine kinase, acylcarnitine profile, and mitochondrial DNA studies for common point mutations and deletion. CMA testing demonstrated a male profile with an approximate 4.8 Mb interstitial deletion on chromosome 9 from band 9q31.2 to 9q32 (chr9: 109195179-113974353, hg 18). This microdeletion including gene content is depicted in Figure 2 .
| Other affected family members
The same 9q31.2q32 microdeletion was segregating amongst the index case's family members with clinical features as summarized in Table 1 Figure 3 .
the 9q31.2q32 region identified in our cohort. Most of these were detected using conventional chromosome banding analysis, and to date, no clear syndrome has been identified [2] [3] [4] [5] [6] [7] [8] ). Seven cases have currently been reported using
CMA techniques with precise breakpoints that overlap the 9q31.2q32 region. [9] [10] [11] [12] [13] These are represented graphically in Figure 3 and aligned against the deletion seen in our cohort, with a summary of the clinical reports available in Figure 2 compares the reported breakpoints, and we suggest a critical region of chr9: 109711873-113407621 (hg 18). Our cohort of novel 9q31.2q32 deletions reveals several candidate genes in which haploinsufficiency may correlate with the phenotypic findings. The KLF4 gene (Kruppellike factor 4, OMIM 602253) is located at 9q31.2 (chr9: 109286956-109291576, hg18). Kruppel-like factor 4 is a transcription factor mainly expressed in the epithelium of the intestine and skin. It has diverse functions in tissue homeostasis and can act as a transcriptional activator/repressor, tumor suppressor, and oncogene.
14 It also has important functions in cell differentiation and has been shown to help transform mouse fibroblasts into an embryonic-like state of pluripotency. 15 Djalilian et al 16 have demonstrated that mice lacking KLF4 have severely underdeveloped epidermal barriers and abnormal expression of the gap junction protein Cx26 (connexin 26, OMIM 121011). Mutations in Cx26 have been linked to sensorineural hearing loss in humans, and altered expression has been shown to adversely affect development of inner hair cells in mouse cochlea. 17 With sensorineural hearing loss being a prominent finding in 9q31.2q32 deletions, haploinsufficiency of KLF4 and subsequent altered expression of Cx26 may be of pathogenic significance. The TXN gene (thioredoxin, OMIM 187700) located at 9q31.3 (chr9: 112046131-112058599, hg18), thioredoxin system and associated isoenzymes are oxidoreductases that scavenge free radicals and play a key role in regulation of transcription and cell growth. 18 Thioredoxin is kept in a reduced state by thioredoxin reductase (TXNRD1, OMIM 601112) and its related isoenzymes. Dammeyer et al 19 found
that TXNRD1 was strongly expressed in rat cochlea and that exposure to cisplatin and oxaliplatin significantly reduced TXNRD1 activity. Tadros et al 20 demonstrated that TXNRD1 expression was downregulated in mice cochlea with age-related hearing loss. These results suggest that the thioredoxin system may play a key role in hearing loss in 9q31.2q32 deletions.
The UGCG gene (UDP-glucose ceramide glucosyltransferase, OMIM 602874) located at 9q31.3 (chr9: 113699027-113735254, hg18) and its gene product catalyses the first step of glycosphingolipid synthesis forming glucosylceramide. This serves as the core component of hundreds of glycosphingolipids, which are important cell membrane components. 21 Rabionet et al 22 demonstrated
that UGCG was important in the maturation of sperm-specific glycosphingolipids. Deletion of UGCG in mouse germ cells caused age-dependent reduction in testicular mass, tubular atrophy, and arrested spermatogenesis. This is of relevance as delayed puberty is one of the common phenotypic features in many male cases with 9q31.2q32 deletions. Our index case was found to have small testes, low testosterone, and a requirement for pubertal induction with testosterone injections. ZNF483 is located at 9q31.3 (chr9: 113327268-113346533, hg18) and while scant information exists as to its function beyond potential transcriptional regulation, 23 numerous groups have identified ZNF483 to be associated with age at menarche in women. [24] [25] [26] [27] [28] A key clinical feature of the female patients in our cohort is that of delayed puberty, potentially reflecting the importance of ZNF483 in the normal onset of puberty. The FRRS1L gene (ferric chelate reductase 1 like, OMIM 604574) is located at 9q31.3 (chr9: 110939402-110969268, hg18) and encodes a component of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are mediators of excitatory glutamatergic neurotransmission. Mutations in FRRS1L have been shown to impair AMPAmediated neurotransmission and lead to an early infantile epileptic-dyskinetic encephalopathy.
29 FRRS1L may be of relevance when considering the propensity of Patients 1-6 to fatigue symptoms, and specifically that Patient III5 symptoms were responsive to modafinil therapy. Modafinil is used in the treatment of excessive somnolence in conditions such as narcolepsy and obstructive sleep apnea. It acts by inhibiting central dopamine and noradrenaline uptake, subsequently increasing extracellular concentrations of dopamine, noradrenaline, serotonin, and glutamate. 30 Modafinil also increases receptor complex levels of several AMPA subtypes in mice. 31 Given that modafinil was effective in a patient with FRRS1L haploinsufficiency, this may suggest a link between FRRS1L, AMPA, and fatigue symptoms in 9q31.2q32 deletions.
With relation to fatigue symptoms, it is also important to consider the MUSK gene (muscle-specific receptor tyrosine kinase, OMIM 601296) which is located at 9q31.3 (chr9: 112470908-112603099, hg18). MUSK encodes kinase proteins that are essential for normal signaling across the neuromuscular junction. Autosomal recessive mutations in MUSK have been associated with congenital myasthenic syndromes 32 ; thus, haploinsufficiency would not be expected to generate clinical symptomatology. Nerve conduction studies and electromyography performed on Patient's IV1 and III5 and 6 were normal suggesting that their fatigue symptoms do not relate to MUSK haploinsufficiency.
In conclusion, our cohort represents a novel contiguous proximal 9q microdeletion which further defines a syndrome for deletions affecting this area. It also narrows a critical region when compared to similar reported cases and provides support for haploinsufficiency of several candidate genes, especially those linked with SNHL, fatigue, and timing of pubertal onset.
